CBAY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CBAY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-04), CymaBay Therapeutics's current share price is $32.48. CymaBay Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $2.03. CymaBay Therapeutics's Cyclically Adjusted PB Ratio for today is 16.00.
The historical rank and industry rank for CymaBay Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, CymaBay Therapeutics's highest Cyclically Adjusted PB Ratio was 16.00. The lowest was 5.53. And the median was 8.72.
CBAY's Cyclically Adjusted PB Ratio is not rankedThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
CymaBay Therapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was $2.567. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.03 for the trailing ten years ended in Dec. 2023.
The historical data trend for CymaBay Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CymaBay Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 3.18 | 4.40 | 5.53 | 7.38 | 11.62 |
For the Biotechnology subindustry, CymaBay Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, CymaBay Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where CymaBay Therapeutics's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
CymaBay Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 32.48 | / | 2.03 | |
= | 16.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CymaBay Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, CymaBay Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:
Adj_Book | = | Book Value per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 2.567 | / | 129.4194 | * | 129.4194 | |
= | 2.567 |
Current CPI (Dec. 2023) = 129.4194.
CymaBay Therapeutics Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201403 | 1.130 | 99.695 | 1.467 |
201406 | 0.842 | 100.560 | 1.084 |
201409 | 1.779 | 100.428 | 2.293 |
201412 | 0.942 | 99.070 | 1.231 |
201503 | 1.198 | 99.621 | 1.556 |
201506 | 1.159 | 100.684 | 1.490 |
201509 | 1.428 | 100.392 | 1.841 |
201512 | 1.199 | 99.792 | 1.555 |
201603 | 0.932 | 100.470 | 1.201 |
201606 | 0.658 | 101.688 | 0.837 |
201609 | 0.436 | 101.861 | 0.554 |
201612 | 0.168 | 101.863 | 0.213 |
201703 | 0.321 | 102.862 | 0.404 |
201706 | 0.074 | 103.349 | 0.093 |
201709 | 1.973 | 104.136 | 2.452 |
201712 | 1.913 | 104.011 | 2.380 |
201803 | 3.614 | 105.290 | 4.442 |
201806 | 3.379 | 106.317 | 4.113 |
201809 | 3.165 | 106.507 | 3.846 |
201812 | 2.866 | 105.998 | 3.499 |
201903 | 3.750 | 107.251 | 4.525 |
201906 | 3.436 | 108.070 | 4.115 |
201909 | 3.094 | 108.329 | 3.696 |
201912 | 2.705 | 108.420 | 3.229 |
202003 | 2.541 | 108.902 | 3.020 |
202006 | 2.404 | 108.767 | 2.860 |
202009 | 2.274 | 109.815 | 2.680 |
202012 | 2.070 | 109.897 | 2.438 |
202103 | 1.851 | 111.754 | 2.144 |
202106 | 1.552 | 114.631 | 1.752 |
202109 | 1.261 | 115.734 | 1.410 |
202112 | 1.570 | 117.630 | 1.727 |
202203 | 1.268 | 121.301 | 1.353 |
202206 | 0.974 | 125.017 | 1.008 |
202209 | 0.711 | 125.227 | 0.735 |
202212 | 0.427 | 125.222 | 0.441 |
202303 | 1.070 | 127.348 | 1.087 |
202306 | 1.108 | 128.729 | 1.114 |
202309 | 2.880 | 129.860 | 2.870 |
202312 | 2.567 | 129.419 | 2.567 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of CymaBay Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles Mcwherter | officer: Chief Scientific Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Daniel Menold | officer: Vice President, Finance | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Paul T Quinlan | officer: General Counsel | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Janet Dorling | director | C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Sujal Shah | director, officer: Chief Executive Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Kurt Von Emster | director | 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080 |
Harish Shantharam | officer: Chief Financial Officer | 7575 GATEWAY BLVD, NEWARK CA 94560 |
Dennis D Kim | officer: Chief Medical Officer | C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803 |
Eric Lefebvre | director | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080 |
Thomas G Wiggans | director | |
Lewis J Stuart | officer: Chief Commercial Officer | 3172 PORTER DRIVE, PALO ALTO CA 94304 |
Venbio Select Advisor Llc | 10 percent owner | 110 GREENE STREET, SUITE 800, NEW YORK NY 10012 |
Behzad Aghazadeh | 10 percent owner | C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012 |
Carl Goldfischer | director | 161 WEST 61ST STREET, NEW YORK NY 10022 |
Robert James Wills | director | 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103 |
From GuruFocus
By Marketwired • 10-23-2023
By Marketwired • 09-21-2023
By Marketwired • 10-31-2023
By Marketwired • 09-11-2023
By GuruFocus Research • 09-20-2023
By Marketwired • 10-16-2023
By GuruFocus Research • 10-11-2023
By PRNewswire • 08-10-2023
By Marketwired • 09-15-2023
By GuruFocus Research • 01-17-2024